dc.contributor.author |
Roehr, Charles Christoph C. |
|
dc.contributor.author |
Banerjee, Rupjani |
|
dc.contributor.author |
Alarcon-Allen, Ana |
|
dc.contributor.author |
Dempsey, Eugene M. |
|
dc.date.accessioned |
2019-05-29T11:28:49Z |
|
dc.date.available |
2019-05-29T11:28:49Z |
|
dc.date.issued |
2019-02-25 |
|
dc.identifier.citation |
Roehr, C. C. C., Banerjee, R., Alarcon-Allen, A. and Dempsey, E. (2019) 'Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes', Cochrane Database of Systematic Reviews, Issue 2, CD013275 (9pp). doi: 10.1002/14651858.CD013275 |
en |
dc.identifier.issued |
2 |
en |
dc.identifier.startpage |
1 |
en |
dc.identifier.endpage |
9 |
en |
dc.identifier.issn |
1465-1858 |
|
dc.identifier.uri |
http://hdl.handle.net/10468/7998 |
|
dc.identifier.doi |
10.1002/14651858.CD013275 |
en |
dc.description.abstract |
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes. |
en |
dc.description.sponsorship |
National Institute for Health Research (Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth) |
en |
dc.format.mimetype |
application/pdf |
en |
dc.language.iso |
en |
en |
dc.publisher |
John Wiley & Sons, Ltd. on behalf of the Cochrane Collaboration |
en |
dc.relation.uri |
https://doi.org//10.1002/14651858.CD013275 |
|
dc.rights |
© 2019, the Cochrane Collaboration. Published by John Wiley & Sons, Ltd. All rights reserved. |
en |
dc.subject |
Methylxanthine |
en |
dc.subject |
Caffeine |
en |
dc.subject |
Cardiorespiratory adaptation |
en |
dc.subject |
Neurodevelopmental outcomes |
en |
dc.title |
Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes |
en |
dc.type |
Other |
en |
dc.internal.authorcontactother |
Eugene Dempsey, Paediatrics & Child Health, University College Cork, Cork, Ireland. +353-21-490-3000 Email: g.dempsey@ucc.ie |
en |
dc.internal.availability |
Full text available |
en |
dc.check.info |
Access to this article is restricted until 12 months after publication by request of the publisher. |
en |
dc.check.date |
2020-02-25 |
|
dc.date.updated |
2019-05-29T11:15:03Z |
|
dc.description.version |
Published Version |
en |
dc.internal.rssid |
487025689 |
|
dc.contributor.funder |
National Institute for Health Research
|
en |
dc.description.status |
Peer reviewed |
en |
dc.identifier.journaltitle |
Cochrane Database of Systematic Reviews |
en |
dc.internal.copyrightchecked |
Yes |
|
dc.internal.licenseacceptance |
Yes |
en |
dc.internal.IRISemailaddress |
g.dempsey@ucc.ie |
en |
dc.identifier.articleid |
CD013275 |
en |
dc.identifier.eissn |
1469-493X |
|